Wells Fargo & Co reaffirmed their market perform rating on shares of Perrigo Company plc (NYSE:PRGO) in a research note published on Friday, April 14th. The firm currently has a $67.00 price objective on the stock.
A number of other brokerages also recently commented on PRGO. Guggenheim reiterated a buy rating and issued a $125.00 target price on shares of Perrigo Company plc in a report on Monday, February 6th. Royal Bank of Canada reiterated a sector perform rating and issued a $85.00 target price (down from $92.00) on shares of Perrigo Company plc in a report on Tuesday, January 17th. Deutsche Bank AG reduced their target price on shares of Perrigo Company plc from $93.00 to $87.00 and set a buy rating for the company in a report on Tuesday, March 14th. Canaccord Genuity set a $86.00 target price on shares of Perrigo Company plc and gave the stock a buy rating in a report on Saturday, March 18th. Finally, Barclays PLC reduced their target price on shares of Perrigo Company plc from $110.00 to $100.00 and set an overweight rating for the company in a report on Monday, February 6th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company’s stock. Perrigo Company plc currently has an average rating of Hold and an average price target of $89.40.
Shares of Perrigo Company plc (NYSE:PRGO) traded up 0.48% on Friday, reaching $70.84. 1,756,948 shares of the company’s stock traded hands. Perrigo Company plc has a 12-month low of $65.47 and a 12-month high of $111.00. The stock has a 50-day moving average of $70.54 and a 200 day moving average of $77.60. The firm’s market cap is $10.16 billion.
TRADEMARK VIOLATION WARNING: “Perrigo Company plc’s (PRGO) Market Perform Rating Reaffirmed at Wells Fargo & Co” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/05/19/perrigo-company-plcs-prgo-market-perform-rating-reaffirmed-at-wells-fargo-co-updated-updated-updated.html.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 13th. Investors of record on Friday, May 26th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Wednesday, May 24th. Perrigo Company plc’s dividend payout ratio is currently -5.53%.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Nova Scotia increased its position in Perrigo Company plc by 2.5% in the first quarter. Bank of Nova Scotia now owns 3,219 shares of the company’s stock valued at $214,000 after buying an additional 80 shares in the last quarter. Janus Capital Management LLC increased its stake in shares of Perrigo Company plc by 2.6% in the first quarter. Janus Capital Management LLC now owns 98,304 shares of the company’s stock worth $6,527,000 after buying an additional 2,501 shares during the period. HighTower Advisors LLC increased its stake in shares of Perrigo Company plc by 271.7% in the first quarter. HighTower Advisors LLC now owns 35,775 shares of the company’s stock worth $2,384,000 after buying an additional 26,151 shares during the period. Blue Sky Asset Management LLC bought a new stake in shares of Perrigo Company plc during the first quarter worth about $1,047,000. Finally, Credit Suisse AG increased its stake in shares of Perrigo Company plc by 13.8% in the first quarter. Credit Suisse AG now owns 241,688 shares of the company’s stock worth $16,046,000 after buying an additional 29,375 shares during the period. 69.65% of the stock is owned by hedge funds and other institutional investors.
About Perrigo Company plc
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
What are top analysts saying about Perrigo Company plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Perrigo Company plc and related companies.